Endocarditis, Bacterial

Experimental Therapeutics
Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis
C. Garcia-de-la-Maria, Y. Q. Xiong, J. M. Pericas, Y. Armero, A. Moreno, N. N. Mishra, M. J. Rybak, T. T. Tran, C. A. Arias, P. M. Sullam, A. S. Bayer, J. M. Miro
Free

Challenging Clinical Case in Antimicrobial Resistance
Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis
Masayuki Nigo, Lorena Diaz, Lina P. Carvajal, Truc T. Tran, Rafael Rios, Diana Panesso, Juan D. Garavito, William R. Miller, Audrey Wanger, George Weinstock, Jose M. Munita, Cesar A. Arias, Henry F. Chambers
Experimental Therapeutics
Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains
Wessam Abdelhady, Arnold S. Bayer, Rachelle Gonzales, Liang Li, Yan Q. Xiong
Mechanisms of Resistance
Daptomycin-Oxacillin Combinations in Treatment of Experimental Endocarditis Caused by Daptomycin-Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus with Evolving Oxacillin Susceptibility (the “Seesaw Effect”)
Soo-Jin Yang, Yan Q. Xiong, Susan Boyle-Vavra, Robert Daum, Tiffanny Jones, Arnold S. Bayer
Experimental Therapeutics
Ceftobiprole Is Superior to Vancomycin, Daptomycin, and Linezolid for Treatment of Experimental Endocarditis in Rabbits Caused by Methicillin-Resistant Staphylococcus aureus
P. Tattevin, L. Basuino, D. Bauer, B. A. Diep, H. F. Chambers
Clinical Therapeutics
Continuous versus Intermittent Infusion of Oxacillin for Treatment of Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus
Darrel W. Hughes, Christopher R. Frei, Pamela R. Maxwell, Kay Green, Jan E. Patterson, George E. Crawford, James S. Lewis
Susceptibility
Relationship between Susceptibility to Daptomycin In Vitro and Activity In Vivo in a Rabbit Model of Aortic Valve Endocarditis
H. F. Chambers, L. Basuino, B. A. Diep, J. Steenbergen, S. Zhang, P. Tattevin, J. Alder
Pharmacology
Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations
Warren E. Rose, Steven N. Leonard, Michael J. Rybak
Experimental Therapeutics
Daptomycin Is Effective in Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus
Francesc Marco, Cristina García de la Mària, Yolanda Armero, Eurídice Amat, Dolors Soy, Asunción Moreno, Ana del Río, Manel Almela, Carlos A. Mestres, José M. Gatell, María Teresa Jiménez de Anta, José M. Miró
and for the Hospital Clinic Experimental Endocarditis Study Group
Clinical Therapeutics
Addition of Rifampin to Standard Therapy for Treatment of Native Valve Infective Endocarditis Caused by Staphylococcus aureus
David J. Riedel, Elizabeth Weekes, Graeme N. Forrest

Pages